ELDN.OQ - Eledon Pharmaceuticals Inc
Guggenheim Securities LLC
ELDN: FY 2025 Earnings In Line; We Look To FDA Feedback On Phase 3 Design For Tegoprubart In Kidney Transplant, Along With Continued Progress in Islet Cell and Xenotransplant
公司
ELDN.OQ
日期
2026-03-20
分析师
Mr. Vamil K. Divan, MD
页数
6 页
需要登录
请登录后购买研报或生成音频内容。